Studien

Indikation	Kurzbezeichnung	EudraCT-Nr.	Phase	Titel
NHL agg	GCT3013-05	2020-003016-27	III	Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma.
NHL agg	PTLD Register	n/a	n/a	Nichtinterventionelle, prospektive Registerstudie zur Behandlungspraxis der PTLD in der klinischen Routine
NHL agg.	CHART Review			Register
NHL agg.	ImbruVeR CHOP	2015-003429-32		Ibrutinib, Bortezomib s.c., Rituximab, CHOP for the treatment of elderly patients (age 61-80 years) with CD20+ diffuse large B-cell lymphoma, IPI ≥ 2
NHL agg.	GCT2013-01	2017-001748-36	I - II	A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma
NHL agg.	Daly2, M-2020-371	2020-003908-14	II	A pivotal Phase II randomised, multi-centre, open-label study to exalsate the effieacy and safety of MB-CÄRTZ{)19.1 compared ta standard af care therapy in participants ltrith relapsed/refractory: diffuse large B-cell lymphorna (R-R DLBCL), who are not eligible for high-dose chemotherapy and autologous stem cell transplantation
NHL agg.	MB-CART2019.1, M-2018-331	2018-001253-27	I - II	A Phase I/II safety, dose finding and feasibility trial of MB-CART2019.1 in patients with relapsed or refractory CD20 and CD19 positive B-NHL
NHL agg.	DSHNHL 2015-1 , NIVEAU	2016-002272-27	n/a	Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to Gemcitabine, Oxaliplatin plus Rituximab in case of CD20+ Disease
NHL agg.	Optimate	2018-002115-96	III	OptiMATe - Optimizing MATRix as remission induction for PCNSL: De-escalated induction treatment in newly diagnosed primary CNS lymphoma – a randomized phase III trial“
CLL	CLL 17	2019-003854-99	III	A phase 3 multicenter, randomized, prospective, open-label trial of ibrutinib monotherapy versus fixed-duration venetoclax plus obinutuzumab versus fixed-duration ibrutinib plus venetoclax in patients with previously untreated chronic lymphocytic leukemia (CLL)
CLL	CLL Frail		II	A PROSPECTIVE, MULTICENTRE PHASE-II TRIAL OF ACALABRUTINIB IN VERY OLD (>80Y) OR FRAIL PATIENTS WITH CLL
CLL	CLL Register	n/a	n/a	Registry of the German CLL Study Group: Long term follow-up of patients with CLL, B-PLL, T-PLL, SLL, T/NK-LGL, HCL and Richter´s transformation
CLL	CLL RT1	2018-002492-17	II	A Prospective, Open-Label, Multicentre Phase-II-Trial To Evaluate The Efficacy And Safety Of Zanubrutinib (BGB-3111), A BTK Inhibitor, Plus Teslelizumab (BGB-A317), A PD-1 Inhibitor, For Treatment Of Patients With Richter Transformation (CLL-RT1-Trial Of The GCLLSG)
MZoL	OLYMP-1	2017-003149-56	II	Phase II, single arm, multicentric, open label, non-randomized: Obinutuzumab in marginal zone lymphoma
MZoL	Marginalzonenlymphom-Register	n/a	n/a	Nicht-interventionelles prospektives Register zu Epidemiologie und Behandlungspraxis bei Marginalzonenlymphomen
NHL ind.	Alternative C	2018-004038-13	II	A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free. Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination with Obinutuzumab in Patients with previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden
AML	IDH2-Post Allo	n/a	n/a	Enasidenib as consolidation or salvage therapy for patients with IDH2 mutated AML or MDS following allogeneic blood stem cell transplantation
ALL	GMALL 08/2013	2013-003466-13	IV	Therapieoptimierung bei erwachsenen Patienten mit neu diagnostizierter akuter lymphatischer Leukämie (ALL) oder lymphoblastischem Lymphom (LBL) durch individualisierte, gezielte und intensivierte Therapie
ALL	ALL-Register	n/a	n/a	GMALL ALL-Register
MPN	IMG-7289-CTP-201	2019-003659-13	II	A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy and Pharmacodynamics of IMG-7289 in Patients with Essential Thrombocythemia
MPN	IMG-7289-CTP-202	2021-002452-37	II	A Multi-Center, Open Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Patients with Myeloproliferative Neoplasms (MPNs) Enrolled in a Prior Bomedemstat Clinical Study
PNH	PNH-Register	n/a	n/a	M07-001, 914007 Register für paroxysmale nächtliche Hämoglobinurie (PNH)
PNH	CLNP023X2201	2017-000888-33	II	An open label, single arm, multiple dose study to assess efficacy, safety, pharmacokinetics and pharmacodynamics of LNP023 when administered in addition to Standard of Care (SoC) in patients with paroxysmal nocturnal hemoglobinuria (PNH) with signs of active hemolysis
PNH	BP39144	2016-002128-10	I/II	An adaptive phase I/II study to assess safety, efficacy, phamacokinetics and pharmacodynamics of RO7112689 in healthy volunteers and patients with paroxysmal nocturnal hemoglobinuria (PNH)
PNH	BO42162 Commodore 2 naive	2019-004931-21	III	A phase 3, randomized, open label, active controlles, multicenter study, evaluating the efficacy and safety of Crovalimab versus Eculizumab in Adult and andolescent patients with paroxismal nocturnal Hemoglobinuria not previously treated with complement inhibitors.
PNH	APL2-307	2019-001106-23	III	An Open Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long Term Safety and Efficacy of APL-2 in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH).
PNH	BO42161 Commodore 1 switch	2019-004931-21	III	A Phase III, randomized, open-label, active-controlled, multicenter study evaluating the efficacy and safety of crovalimab versus eculizumab in adult and adolescent patients with PNH currently treated with complement inhibitors
PNH	CLNP023C12302	2019-004665-40	III	A randomized, multicenter, active-comparator controlled, open label trial to evaluate efficacy and safety of oral, twice daily LNP023 in adult patients with PNH and residual anemia, despite treatment with an intravenous anti-C5 antibody
PNH	CLNP023C12301	2020-003172-41	III	A multicenter, single-arm, open-label trial to evaluate efficacy and safety of oral, twice daily iptacopan in adult PNH patients who are naive to complement inhibitor therapy
PNH	RavuReWo	n/a	III	Analysis/Outcomes of Patients who switched from being under eculizumab to ravulizumab treatment in a real-world setting – according to the label but not included in Phase 3 studies RavuReWo
Anämie	MOM-M281-006	2019-000720-17	II - III	Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study with a Long-term Open-label Extension
Anämie	EMAA 9345	2014-000174-19	II - III	Efficacy and Safety of Eltrombopag in Patients with Acquired Moderate Aplastic Anemia (EMAA) who are treated with Ciclosporin A. Prospective Randomized Multicenter Study comparing Thrombopoetin-Receptor agonist Eltrombopag (Revolade ®, GlaxoSmithKline) with Placebo in Patients with Acquired Moderate Aplastic Anemia who are treated with Ciclosporin A
Anämie	C-935788-058 (Extension)	2019-001882-34	III	A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
CAD	PDY16370 BIVV020	2019-001844-22	1b	A multicenter, Phase 1b, open label, nonrandomized, single dose study evaluating the safety, tolerability and activity of BIVV020 in adults with cold agglutinin disease
CAD	ACT16832	2020‐003880‐24	1b - II	A multicenter, open-label, Phase 1b/2 study to evaluate the safety, pharmacokinetics, and efficacy of subcutaneous isatuximab in patients with primary warm autoimmune hemolytic anemia
CAD	LTS16637	2019-004423-21	1b	An open label, long term, safety and tolerability study of patients with cold agglutinin disease previously treated with BIVV020
ITP	ARGX-113-1803	2019-002100-41	III	A Long-Term, Single-Arm, Open-Label, Multicenter, Phase III Follow-On Trial to Evaluate Safety and Efficacy of Intravenous Efgartigimod (ARGX-113) in Adult Patients with Primary Immune Thrombocytopenia
ITP	ARGX-113-1801	2019-002100-41	III	A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Efgartigimod (ARGX-113) 10 mg/kg Intravenous in Adult Patients with Primary Immune Thrombocytopenia
ITP	PDY16894	2020-00416-18	Iia	A multicenter, phase 2a, open label, nonrandomized study evaluating the efficacy, safety, and tolerability of BIVV020 in adults with chronic immune thrombocytopenia (ITP)”
ITP / CAD	CLNP023L12201	2021-002039-40	II	An open-label, multi-center, phase 2 basket study to assess efficacy, safety and pharmacokinetics of iptacopan(LNP023) in participants with autoimmune benignhematological disorders
Waiha	ANX-wAIHA-01	n/a	n/a	“A Study to Evaluate the Complement Signature of Subjects with Warm Autoimmune Hemolytic Anemia “
MM	Regeneron 5458-ONC-1826	n/a	I - II	PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
MM	GMMG-CONCEPT	2016-000432-17	II	Eine klinische Phase II Studie zur Induktions-, Konsolidierungs- und Erhaltungstherapie mit Isatuximab, Carfilzomib, Lenalidomid und Dexamethason (I-KRd) in der Primärtherapie des Hochrisikomyeloms
AL-Amyloidose	CAEL301-301	2019‐004254‐28	III	A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIa AL Amyloidosis
AL-Amyloidose	CAEL301-302	2020-000713-32	III	A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIb AL Amyloidosis
AL-Amyloidose	Amyloidose Register	n/a	n/a	Nationales klinisches Amyloidose-Register

Kontakt